logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

In PDAC with BRCA/PALB2 mutations, a potential standard treatment

The authors suggest that cisplatin+gemcitabine should be the standard approach for untreated PDAC.